Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma

• Published in: OncoTargets and therapy Vol. 11; pp. 6879 - 6886
• Main Authors: Okuno, Kazuma, Matsubara, Takao, Nakamura, Tomoki, Iino, Takahiro, Kakimoto, Takuya, Asanuma, Kunihiro, Matsumine, Akihiko, Sudo, Akihiro
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Analysis; Anthracyclines; Bone cancer; Bone surgery; Breast cancer; Cancer therapies; Carbonic anhydrases; Cell adhesion & migration; Cell culture; Cell cycle; Cell growth; Cell viability; Chemotherapy; Development and progression; Health aspects; Hypoxia; Immunohistochemistry; Medical prognosis; Metastasis; Original Research; Orthopedics; Osteosarcoma; Proteins; Sarcoma; Tumors; United Kingdom > UK; United States > US; Japan; hypoxia; carbonic anhydrase IX; inhibitor; osteosarcoma
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S177605

We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma.
CA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry.
Treatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively.
CA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance.